Azithromycin

Introduction Overview

Generic Name

azithromycin

Brand Name

Zithromax

Dosage Form

oral tablets, oral suspension, extended-release microspheres for suspension, injectable solution

Drug Class

Macrolides

Pharmacokinetics

Absorption: Azithromycin (Zithromax) is rapidly absorbed following oral administration with a bioavailability of approximately 37%. Peak plasma concentrations are typically reached within 2 to 3 hours post-dose. The absorption is not significantly affected by food, permitting administration with or without meals. The pharmacokinetic profile is characterized by a large volume of distribution, reflecting extensive tissue uptake. Enteric-coated and extended-release formulations have been developed to improve dosing convenience.

Distribution: Azithromycin exhibits extensive tissue distribution exceeding plasma concentrations by several folds. Plasma protein binding is moderate (approximately 51%-54%). The drug achieves high concentrations in tissues such as the lungs, tonsils, skin, and genital tract, with tissue levels maintained for several days post-treatment. This extensive distribution is attributed to azithromycin's high affinity for tissue macrophages and fibroblasts, facilitating intracellular penetration and sustained antimicrobial activity. Notably, tissue concentrations greatly exceed minimum inhibitory concentrations for sensitive pathogens.

Metabolism: Azithromycin undergoes minimal hepatic metabolism. It is not significantly metabolized by cytochrome P450 enzymes, reducing the potential for metabolic drug interactions common with other macrolides. The primary metabolic pathway involves N-demethylation and deoxidation, occurring to a limited extent. The low metabolic rate contributes to azithromycin's prolonged half-life and sustained activity.

Elimination: Azithromycin is predominantly eliminated via biliary excretion into the feces, with approximately 50% of the administered dose recovered in feces within several days. Renal excretion accounts for a minor elimination route (~6%-14%). The terminal elimination half-life ranges from 68 to 73 hours, supporting once-daily dosing and short-course therapies. The prolonged half-life is a clinical advantage, permitting shorter duration dosing regimens while maintaining therapeutic drug levels. In patients with hepatic impairment, azithromycin clearance may be altered, warranting cautious use.

Dosage Forms

Available Dosage Forms: Zithromax is available in multiple formulations, including:
- Oral tablets: 250 mg, 500 mg
- Extended-release microspheres for suspension (Zmax): 2 grams single dose
- Oral suspension (reconstituted liquid): 100 mg/5 mL; 200 mg/5 mL
- Injectable solution for intravenous use

Dosages for Adults and Adolescents: Dosage varies by infection type, severity, and patient weight. Common adult dosing includes:
- For mild to moderate infections (e.g., pharyngitis, skin infections): 500 mg on day 1 followed by 250 mg once daily on days 2-5
- For community-acquired pneumonia: usually 500 mg once daily for 3 days
- For sexually transmitted infections (chlamydia): a single 1 gram oral dose
- For extended-release formulations (Zmax), a single 2 gram dose is used for uncomplicated infections

Specific Patient Populations: In pediatric patients older than 6 months, dosing is weight-based:
- For otitis media and respiratory infections: 10 mg/kg on day 1, followed by 5 mg/kg on days 2 through 5

Patients with hepatic or renal impairment require no specific dose adjustment, but careful monitoring is advised.

Dosing regimens are adapted according to the infection being treated and susceptibility patterns. Complete adherence to the prescribed course is essential to minimize resistance development.

Mechanism Of Action

Azithromycin is a macrolide antibiotic that exerts its antibacterial effect by binding reversibly to the 50S ribosomal subunit of susceptible microorganisms. This binding inhibits the translocation steps of protein synthesis, effectively halting bacterial growth by preventing peptide chain elongation. By targeting bacterial ribosomes, azithromycin impairs synthesis of essential proteins needed for bacterial survival and replication.

At a cellular level, azithromycin accumulates within phagocytes and fibroblasts, facilitating high intracellular concentrations. This allows effective penetration into infected tissues and sites where intracellular pathogens reside. The drug's ability to concentrate inside cells contributes to its efficacy against atypical organisms such as Chlamydia trachomatis and Mycoplasma pneumoniae.

Biochemically, azithromycin's binding differs slightly from that of erythromycin, imparting greater acid stability and a broader antimicrobial spectrum. Its chemical structure confers increased resistance to bacterial efflux pumps and reduced degradation by bacterial enzymes, enhancing activity against resistant strains.

Clinically, the prolonged half-life and extensive tissue distribution support once-daily dosing and short-course treatment regimens. Research comparing azithromycin to other macrolides demonstrates comparable or superior efficacy in respiratory and sexually transmitted infections, with a favorable safety profile. Studies also reveal immunomodulatory effects, such as decreased production of pro-inflammatory cytokines, which may contribute beneficially in chronic airway diseases.

Pharmacological Actions

Inhibition of bacterial protein synthesis via binding to 50S ribosomal subunit
Bacteriostatic and, at higher concentrations, bactericidal activity against susceptible bacteria
Broad-spectrum antimicrobial activity against gram-positive, gram-negative, and atypical pathogens
Concentration-dependent tissue accumulation facilitating intracellular pathogen targeting
Long elimination half-life supporting sustained antimicrobial effects
Immunomodulatory properties including modulation of cytokine production
Activity against respiratory tract pathogens including Streptococcus pneumoniae and Haemophilus influenzae
Effective against sexually transmitted pathogens such as Chlamydia trachomatis and Neisseria gonorrhoeae
Minimal cytochrome P450 interactions reducing potential for metabolic drug interactions
Stability in acidic environments, enhancing oral bioavailability
Reduced susceptibility to bacterial resistance mechanisms compared to earlier macrolides
Excretion primarily via biliary route minimizing renal toxicity risks
Ability to penetrate biofilms enhancing efficacy in chronic infections
Compatibility with short-course dosing improving compliance rates
Potential adjunctive use in inflammatory airway diseases due to anti-inflammatory effects

Therapeutic Or Clinical Uses

Treatment of acute bacterial sinusitis and pharyngitis caused by susceptible organisms
Management of community-acquired pneumonia
Therapy for acute exacerbations of chronic bronchitis
Treatment of uncomplicated skin and skin structure infections
Management of sexually transmitted infections including chlamydia and gonorrhea
Prophylaxis and treatment of Mycobacterium avium complex (MAC) infections in AIDS patients
Treatment of otitis media in pediatric patients
Off-label use in certain atypical infections caused by Legionella pneumophila
Therapy for bacterial infections of the ears (otitis externa and media)
Adjunct treatment in inflammatory airway diseases such as cystic fibrosis
Alternative antibiotic for patients allergic to penicillins
Treatment of infections caused by susceptible strains of Staphylococcus aureus
Use in travelers returning with bacterial respiratory infections
Management of urethritis and cervicitis due to bacterial pathogens
As part of combination therapy for eradication of Helicobacter pylori

Side Or Adverse Effects

Diarrhea and gastrointestinal disturbances including nausea and abdominal pain
Vomiting and dyspepsia
Headache and dizziness
Transient elevation of liver enzymes and potential hepatotoxicity
Allergic reactions such as rash, itching, and urticaria
Severe hypersensitivity reactions including anaphylaxis and Stevens-Johnson syndrome
QT interval prolongation leading to risk of torsades de pointes in susceptible individuals
Cardiac arrhythmias including palpitations and ventricular tachycardia
Hearing loss or tinnitus, particularly with prolonged therapy
Superinfection with resistant organisms including Clostridioides difficile-associated diarrhea
Injection site reactions with intravenous formulations such as pain and phlebitis
Rare cases of pancreatitis
Fatigue and malaise
Myasthenia gravis exacerbation due to neuromuscular blockade
Photosensitivity reactions increasing risk of sunburn

Precautions

Use with caution in patients with history of liver disease or previous liver injury from azithromycin
Avoid use in patients with known QT prolongation or congenital long QT syndrome
Monitor cardiac function in patients with underlying heart rhythm disorders
Exercise caution in patients with myasthenia gravis due to risk of muscle weakness exacerbation
Avoid concomitant use with drugs known to prolong QT interval
Do not administer to children younger than 6 months of age
Inform patient about possibility of photosensitivity and recommend sun protection measures
Use with caution in patients with renal impairment, although specific dose adjustment generally not required
Warn patients about potential gastrointestinal adverse effects and signs of severe diarrhea
Assess risk versus benefit in pregnant and breastfeeding women; use only if clearly needed
Avoid concurrent use of aluminum or magnesium-containing antacids within 2 hours of dosing
Ensure full course of therapy is completed to prevent resistance development
Evaluate for possible drug interactions prior to initiation
Cautious use in elderly patients due to increased risk of cardiac events
Discuss importance of adherence to prescribed dosing to optimize outcomes

Warnings

Do not use if patient has experienced jaundice or liver dysfunction due to azithromycin
Risk of serious allergic reactions including anaphylaxis may occur
Potential for severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis
Reports of prolongation of the QT interval and fatal cardiac arrhythmias, including torsades de pointes
Discontinue immediately if signs of liver toxicity develop, such as jaundice or dark urine
May cause Clostridioides difficile-associated diarrhea, which can be severe or fatal
Use with caution in patients with pre-existing heart conditions or electrolyte abnormalities
Risk of worsening symptoms in myasthenia gravis patients including respiratory failure
Avoid unnecessary use to reduce risk of antibiotic resistance
Not effective for viral infections such as common cold or influenza
Careful monitoring recommended when administering to elderly or critically ill patients
Possibility of increased side effects when combined with other QT-prolonging medications
Ensure accurate dosing in pediatric patients to prevent under or overdosing
Watch for signs of secondary fungal infections during or after therapy
Advise patients to report any severe or persistent adverse effects promptly

Contraindication

Known hypersensitivity to azithromycin or other macrolide antibiotics such as clarithromycin or erythromycin
History of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use
Patients with known congenital long QT syndrome
Hypersensitivity to any components of the formulation
Use contraindicated in patients with a history of severe allergic reactions to macrolide antibiotics
Caution contraindicated during breastfeeding unless benefits outweigh risks
Not indicated in children under 6 months of age due to safety concerns
Avoid in patients with documented torsades de pointes or marked QT prolongation
Contraindicated in patients with severe hepatic impairment or acute liver failure
Avoid concomitant use with drugs that strongly inhibit cytochrome P450 3A4 with caution due to interaction potential
Should not be used in viral infections where bacterial etiology is not established
Contraindicated in individuals with known prolonged arrhythmias related to prior macrolide therapy
Not recommended for intraocular or topical use
Absolute contraindication in cases of macrolide-induced cholestatic hepatitis
Avoid use in patients with severe hypersensitivity reactions such as Stevens-Johnson syndrome attributed to macrolides

Drug Interactions

Concurrent use with warfarin and other oral anticoagulants can increase risk of bleeding
Nelfinavir coadministration increases azithromycin plasma concentrations; monitor for toxicity
Aluminum or magnesium-containing antacids can decrease azithromycin absorption if taken within 2 hours
Potential additive QT prolongation when combined with other QT-prolonging drugs such as amiodarone or quinidine
Coadministration with cyclosporine may increase cyclosporine levels; monitor renal function
Potential interaction with digoxin leading to increased digoxin levels
May interfere with metabolism of theophylline, requiring monitoring for toxicity
Rifabutin coadministration can reduce azithromycin efficacy by inducing metabolism
Azithromycin may increase the serum levels of drugs metabolized by CYP3A4, though less than other macrolides
Antacids containing calcium do not significantly affect azithromycin absorption
Increased risk of adverse effects when combined with statins metabolized by CYP3A4
Possible interaction with ergot derivatives leading to ergot toxicity
Concomitant use with oral hypoglycemic agents may enhance hypoglycemic effect
Use with caution when administered with other hepatotoxic drugs
Herbal supplements such as St. John’s wort may reduce azithromycin efficacy by inducing metabolism

Preparations Of The Drug

Azithromycin oral tablets: available in 250 mg and 500 mg strengths for standard dosing
Oral suspension formulations: 100 mg/5 mL and 200 mg/5 mL for pediatric and adult dose flexibility
Extended-release microspheres for suspension (Zmax): 2 gram single-dose formulation
Intravenous solution: used for patients unable to take oral formulations or severe infections
Powder for intravenous infusion requiring reconstitution prior to administration
Combination formulations with anti-malarial agents for specialized indications (investigational)
Single-dose packets (Z-Pak) containing 6 tablets for ease of use and compliance
Multi-dose packaging (Tri-Pak) with 3 tablets for 3-day total dosing
Preservative-free formulations available for intravenous use in sensitive patients
Pediatric reconstitutable powder preparations with flavorings to improve palatability
Topical azithromycin ophthalmic solutions available separately but not under brand Zithromax
Generic azithromycin preparations equivalent in dose and bioavailability to brand products
Bulk powder forms for compounding customized dosage forms in specialized pharmacy settings
Enteric-coated formulations designed to improve gastrointestinal tolerability
Parenteral formulations used in hospital setting for serious infections